Cited 0 times in
Cilostazol inhibits the expression of hnRNP A2/B1 and cytokines in human dermal microvascular endothelial cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 최민주 | - |
dc.date.accessioned | 2023-08-09T02:35:36Z | - |
dc.date.available | 2023-08-09T02:35:36Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 0392-856X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195659 | - |
dc.description.abstract | Objectives: hnRNP A2/B1 has been identified as a target antigen of anti-endothelial cell IgA antibody in patients with Behçet's disease (BD). In addition, increased expression of cellular hnRNP A2/B1 is stimulated by Streptococcus sanguinis or the sera from patients with BD. We aimed to investigate the effects of cilostazol on the expression of hnRNP A2/B1 and chemokines in human dermal microvascular endothelial cells (HDMECs). Methods: Expression of hnRNP A2/B1, cytokines, and chemokines in HDMECs was induced by tumour necrosis factor (TNF)-α, interleukin (IL)-1β, and lipopolysaccharide (LPS). HDMECs were treated with cilostazol (10 μM) and the inhibitory effects were evaluated with real-time polymerase chain reaction and immunocytochemistry. Results: Expression of hnRNP A2/B1, CXCL1, CXCL2, CXCL8, and IL-1β mRNA was significantly increased in HDMECs treated with all three stimulants. In addition, mRNA expression of hnRNP A2/B1 and inflammatory mediators was significantly inhibited in HDMECs treated with various stimulants with cilostazol pretreatment. Immunocytochemistry demonstrated that cilostazol pretreatment effectively inhibited the stimulant-induced increased expression of hnRNP A2/B1 in the nucleus and cytoplasm of HDMECs. Conclusions: Cilostazol pretreatment can reduce the excessive expression of inflammatory cytokines and chemokines and hnRNP A2/B1 by the BD-related stimulants, including TNF-α, IL-1β, and LPS, in HDMECs. We suggest that cilostazol may have therapeutic efficacy in inhibiting the major inflammatory reaction in the pathogenesis of BD. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Clinical And Experimental Rheumatology S.A.S | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Anti-Inflammatory Agents / pharmacology* | - |
dc.subject.MESH | Behcet Syndrome / drug therapy* | - |
dc.subject.MESH | Behcet Syndrome / genetics | - |
dc.subject.MESH | Behcet Syndrome / immunology | - |
dc.subject.MESH | Behcet Syndrome / metabolism | - |
dc.subject.MESH | Cells, Cultured | - |
dc.subject.MESH | Cilostazol | - |
dc.subject.MESH | Cytokines / genetics | - |
dc.subject.MESH | Cytokines / immunology | - |
dc.subject.MESH | Cytokines / metabolism* | - |
dc.subject.MESH | Cytokines / pharmacology | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Endothelial Cells / drug effects* | - |
dc.subject.MESH | Endothelial Cells / immunology | - |
dc.subject.MESH | Endothelial Cells / metabolism | - |
dc.subject.MESH | Gene Expression Regulation | - |
dc.subject.MESH | Heterogeneous-Nuclear Ribonucleoprotein Group A-B / genetics | - |
dc.subject.MESH | Heterogeneous-Nuclear Ribonucleoprotein Group A-B / immunology | - |
dc.subject.MESH | Heterogeneous-Nuclear Ribonucleoprotein Group A-B / metabolism* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lipopolysaccharides / pharmacology | - |
dc.subject.MESH | Microvessels / drug effects* | - |
dc.subject.MESH | Microvessels / immunology | - |
dc.subject.MESH | Microvessels / metabolism | - |
dc.subject.MESH | RNA, Messenger / genetics | - |
dc.subject.MESH | RNA, Messenger / metabolism | - |
dc.subject.MESH | Skin / blood supply* | - |
dc.subject.MESH | Tetrazoles / pharmacology* | - |
dc.subject.MESH | Time Factors | - |
dc.title | Cilostazol inhibits the expression of hnRNP A2/B1 and cytokines in human dermal microvascular endothelial cells | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Dermatology (피부과학교실) | - |
dc.contributor.googleauthor | Yinghua An | - |
dc.contributor.googleauthor | Zhenguo Zheng | - |
dc.contributor.googleauthor | Xianglan Zhang | - |
dc.contributor.googleauthor | Sung Bin Cho | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Min Ju Choi | - |
dc.contributor.googleauthor | Dongsik Bang | - |
dc.contributor.localId | A00384 | - |
dc.contributor.localId | A04057 | - |
dc.relation.journalcode | J00555 | - |
dc.identifier.eissn | 1593-098X | - |
dc.identifier.pmid | 28850024 | - |
dc.identifier.url | https://www.clinexprheumatol.org/abstract.asp?a=11437 | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 최민주 | - |
dc.citation.volume | 35 Suppl 108 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 60 | - |
dc.citation.endPage | 66 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, Vol.35 Suppl 108(6) : 60-66, 2017-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.